Table 3.
Summary of multivariable Cox regression results for PFS and OS. HR (95% CI) results for statistically significant predictors are in bold.
| Outcome measure | PFS |
OS |
||
|---|---|---|---|---|
| HR (95% CI) | p-Value | HR (95% CI) | p-Value | |
| Age (continuous) | 0.975 (0.917–1.036) | 0.413 | 1.015 (0.949–1.086) | 0.655 |
| PS (categorical): 0–1 as reference vs 2-4 | 3.132 (1.972–4.973) | < 0.001 | 3.638 (2.159–6.130) | < 0.001 |
| Starting dose (categorical): 125 mg as reference vs < 125 mg | 1.459 (0.685–3.104) | 0.327 | 1.883 (0.722–4.912) | 0.196 |
| Dose reduction (categorical): no as reference vs yes | 0.814 (0.507–1.304) | 0.391 | 0.535 (0.309–0.927) | 0.026 |
| Dose delay (categorical): no as reference vs yes | 0.425 (0.269–0.672) | < 0.001 | 0.393 (0.232–0.665) | 0.001 |
| Baseline ACCI (continuous) | 1.260 (1.033–1.536) | 0.022 | 1.236 (0.990–1.543) | .061 |
| Number of metastatic sites (continuous) | 1.491 (1.253–1.775) | < 0.001 | 1.471 (1.201–1.801) | 0.001 |
Abbreviations: ACCI = Age-adjusted Charlson Comorbidity Index; CI = confidence interval; HR = hazard ratio; PFS = progression-free survival; PS = performance status; OS = overall survival.